1994年1月から2009年11月までのProMED-mail アーカイブをキーワード「pertussis Japan」でand検索しても、日本における百日咳の情報(英語)は1件も(当感染症データベースに)ありません。
青少年用・成人用百日咳ワクチン
追加免疫 booster のため1回のみ接種
3種混合ワクチン DTaPであるが、乳幼児用とは成分比率等が違う。
ProMED-mail 20050511.1293
Published Date 11-MAY-2005
Subject Pertussis, adolescent vaccine – USA
FDA URLリンク切れ
fda.gov/bbs/topics/ANSWERS/ 2005/ANS01354.html
ワクチン製品名 Boostrix
製造メーカー GlaxoSmithKline
接種対象 青少年(年齢10-18歳) のみ
FDA 承認 3 May 2005
Boostrix has the same components as Infanrix, a DTaP vaccine for infants and young children, but in reduced quantities.
ProMED-mail 20050614.1669
Published Date 14-JUN-2005
Subject Pertussis, adult vaccine – USA
FDA URLリンク切れ
fda.gov/bbs/topics/ANSWERS/ 2005/ANS01361.html
ワクチン製品名 Adacel
製造メーカー Aventis Pasteur Limited
接種対象 青少年および成人 年齢 11-64歳
FDA 承認 10 Jun 2005
the diphtheria toxoid and one of the pertussis components are in reduced quantities
FDA記事一部引用
The disease [whooping cough, pertussis] is generally less severe in adolescents, but it is thought that they might transmit the disease to susceptible infants and other family members.
The FDA today, 10 Jun 2005, approved a new vaccine for a single booster immunization against pertussis (whooping cough), in combination with tetanus and diphtheria, for adolescents and adults 11-64 years of age. The vaccine will be marketed as Adacel by Aventis Pasteur Limited located in Toronto, Canada.
The vaccine is a Tetanus Toxoid (T), Reduced Diphtheria Toxoid (d) and Acellular Pertussis Vaccine (ap), Adsorbed. It contains the same components as DTaP vaccine indicated for infants and children, but the diphtheria toxoid and one of the pertussis components are in reduced quantities.
Recently, FDA approved a similar vaccine called Boostrix, manufactured by GlaxoSmithKline, for use in adolescents 10-18 years of age.
Among adolescent recipients of this vaccine, injection site pain and low-grade fever were observed more frequently than among those who received Td vaccine. Rates of adverse reactions were similar in adults receiving this vaccine or receiving Td vaccine.
